<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/29A2BEEA-27F5-4710-BE79-830C96C4C0B2"><gtr:id>29A2BEEA-27F5-4710-BE79-830C96C4C0B2</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Tuplin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/83E8A224-4F6F-4A77-B14A-00EBE25D9CC1"><gtr:id>83E8A224-4F6F-4A77-B14A-00EBE25D9CC1</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Evans</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100139"><gtr:id>DCC50D8F-1897-4F78-B3E9-4432FE721A22</gtr:id><gtr:title>Interplay of RNA structure, protein and miRNA binding in early replication events of hepatitis C virus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100139</gtr:grantReference><gtr:abstractText>Hepatitis C virus (HCV) is an important viral pathogen infecting approximately 3% of the global population. HCV infection results in chronic liver disease, cirrhosis and hepatocellular carcinoma. Current anti-viral therapies are poorly effective and there is little prospect of developing a vaccine to prevent infection. There are two significant challenges to the development of new anti-viral therapies; firstly we have only an incomplete understanding of how the virus controls critical events in its life cycle, particularly during the early stages of infection when there are only low viral levels. Secondly, virus replication generates large populations of variant progeny viruses, these include variants resistant to anti-viral drugs. We have identified a novel interaction between a cellular protein and the nucleic acid of the virus. Inhibition of this interaction ? by preventing the protein from binding to the virus genome ? significantly reduces the ability of the virus to replicate. This is achieved by inhibiting a key early process in the life cycle termed translation. The result of this inhibition is that the viral yield is reduced. We predict ? based on our own work and that of others ? that the binding protein stabilizes the virus genome in a particular conformation and that disrupting this conformation is detrimental for virus replication. To understand this process better we propose to conduct three sets of experiments; 1) we will measure changes in the structure of the virus genome to confirm whether it undergoes the structural changes we predict, 2) we will identify the protein and develop reagents that will allow us to determine how it functions ? for example, we will test if it only present in liver cells, we will investigate whether it changes in uninfected and virus infected cells (we predict it does), either in quantity, location or by chemical modification. 3) we will conduct functional studies to investigate the importance of this protein to the virus life cycle. For example, we will deplete the protein from cells and see if this reduces the yield of virus and, specifically, whether it reduces the key translation events in the virus life cycle. 
All viruses are parasites that subvert cellular processes to favour their own replication. If, as we predict, the genomic structure of HCV is somehow stabilized by ?stealing? a cellular protein from liver cells, then inhibition of this process may allow the development of novel, effective anti-viral therapies.</gtr:abstractText><gtr:technicalSummary>Hepatitis C virus (HCV) is a globally important human pathogen. With little or no prospect of a vaccine to prevent infection and only partially effective antivirals, we urgently need to identify therapeutic targets to which new drugs can be directed. This means we need an improved understanding of how the virus replicates. HCV is a small single-stranded RNA virus; initial translation of the infecting genome must be terminated to enable negative-strand synthesis, a process achieved in similar viruses by a feedback loop responsive to viral and/or cellular proteins. These often mediate control by interacting with RNA structures in the virus genome. We have defined a specific protein-RNA interaction with a stem-loop (SL87) known to be implicated in viral translation. We hypothesise that binding of this protein is involved in the control of viral translation. We propose this process is also influenced by changes in the template RNA structure and interaction with miR-122, a hepatocyte-specific micro-RNA implicated in HCV replication and possibly involved in ribosome recruitment. Interplay of these three-components (RNA, protein, micro-RNA) determines the critical translation to replication switch, inhibition of which would be a valid and tempting target for development of HCV therapies.
Our study has three objectives.
1) To use our extensive experience in RNA structure analysis to accurately quantify the structure ? and structural changes ? of the HCV genome in cytoplasmic extracts of cells that support virus replication, and to investigate the structural influence of a) mutations that inhibit translational control, b) the interaction with miR-122 and c) protein binding to SL87. 
2) To identify and characterize the protein that binds to SL87. Using affinity purification and mass spectroscopy we will identify SL87, define the precise SL87 binding site my mutagenesis and footprinting, generate tagged (e.g. GFP) derivatives for colocalisation studies and reagents (e.g. antisera and siRNA) for studies investigating the distribution and depletion of the protein.
3) To conduct functional studies of virus replication and translation with genome templates of known structure ? to enable the role of structure in translational control to be determined ? and in systems that allow depletion/supplementation with micro-RNA and proteins to determine how control is mediated.
These studies will improve understanding of a key stage in the early replication of HCV. Cellular proteins usurped by viruses may provide valid invariant targets for development of novel antiviral therapies, that help avoid the problems caused by virus variation and rapid evolution.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>468978</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Edinburgh Infectious Diseases</gtr:department><gtr:description>PS</gtr:description><gtr:id>9D44EB6E-FF9C-40A4-A964-FA0DF743D102</gtr:id><gtr:impact>19091869 18799591 18684812 18319285
Research is multi-disciplinary, with PD contributing bioinformatic expertise.</gtr:impact><gtr:outcomeId>6F6174F0F80-1</gtr:outcomeId><gtr:partnerContribution>Intellectual, joint supervision, joint grant applications</gtr:partnerContribution><gtr:piContribution>Intellectual, shared supervision and joint grant applications to research councils and charities.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>37500</gtr:amountPounds><gtr:country>Guernsey, Bailiwick of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cogent</gtr:description><gtr:fundingOrg>Cogent</gtr:fundingOrg><gtr:id>4F91E03C-E7F7-4940-8ACD-5CC106008915</gtr:id><gtr:outcomeId>tZLCodqqKKk</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Therapeutic target identified and inhibitors designed</gtr:description><gtr:grantRef>G1100139</gtr:grantRef><gtr:id>4EB84BF7-379B-42FD-A189-176F90D9A15A</gtr:id><gtr:impact>PhD. funding from Cogent Ltd.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>546341c78f1ac7.61425784</gtr:outcomeId><gtr:patentId>PCT/GB2014/050943</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>INHIBITOR FOR TREATMENT OF HCV</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1F547CE5-9CD8-4BB9-A786-9B6C143F33D7</gtr:id><gtr:title>Recombination in enteroviruses is a biphasic replicative process involving the generation of greater-than genome length 'imprecise' intermediates.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01d178940a6ca727fbfa99fa03b6b009"><gtr:id>01d178940a6ca727fbfa99fa03b6b009</gtr:id><gtr:otherNames>Lowry K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_540e17ae17a3510e3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2C85C60-2911-41BB-BE59-0CA740A613CE</gtr:id><gtr:title>Inhibition of HCV translation by disrupting the structure and interactions of the viral CRE and 3' X-tail.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8138cbb798b1a950c346b3c2e61a1f25"><gtr:id>8138cbb798b1a950c346b3c2e61a1f25</gtr:id><gtr:otherNames>Tuplin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5675e0153791d</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100139</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>